We’re moving people out of the criminal justice system instead of into it, we’re saving resources, we’re saving taxpayer ...

AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...

The S&P 500 Index ($SPX) (SPY) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.69%, and ...

The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.02%, and the Nasdaq ...

Jacob Ballon, MD, MPH, of Stanford University in California, discussing research evaluating the impact of different antipsychotics on the cognitive symptoms of schizophrenia. "There is no clear ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, ...

Teva Pharmaceuticals’ TEV-‘749 (olanzapine) has shown statistical improvement in schizophrenia symptoms in a Phase III trial. The Phase III SOLARIS trial (NCT05693935) demonstrated ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to ...

today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

Symptoms of schizophrenia, a serious mental disorder that can include hallucinations and delusions, vary greatly from person to person. One common group of schizophrenia symptoms that doesn’t ...

Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant ...